^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
120O-Pembrolizumab (Pembro) With or Without Lenvatinib (Lenva) in First-Line Metastatic NSCLC With PD-L1 TPS >=1% (LEAP-007): A Phase 3, Randomized, Double-Blind Study
Published date:
12/02/2021
Excerpt:
Pembrolizumab (Pembro) With or Without Lenvatinib (Lenva) in First-Line Metastatic NSCLC With PD-L1 TPS ≥1%...Median PFS was longer and ORR was higher with pembro + lenva vs pembro + pbo…
Trial ID:
Source:
Title:
An open-label, single-arm phase II study of pembrolizumab plus lenvatinib in PD-L1 positive patients with TKI-resistant EGFR-mutated advanced non-small cell lung cancer
Excerpt:
...Tumor tissue showing PD-L1 expression (TPS >= 1%) in >= 1% of tumor cells as assessed by IHC 22C3 pharmDx; Note: must be derived from archived tumor samples or new tumors from previously unirradiated tumor lesions PD-L1 expression was assessed in obtained core or excisional biopsies. ...
Trial ID:
Source:
Title:
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)
Excerpt:
...- Has tumor tissue that demonstrates programmed cell death-ligand 1 (PD-L1) expression in ≥1% of tumor cells (Tumor Proportion Score [TPS] ≥1%) as assessed by immunohistochemistry (IHC) 22C3 pharmDx assay (Dako North America, Inc.) at a central laboratory....
Trial ID:
More C2 evidence
Source:
Title:
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study
Excerpt:
...- Has tumor tissue that demonstrates programmed cell death-ligand 1 (PD-L1) expression in ≥1% of tumor cells (Tumor Proportion Score [TPS] ≥1%) as assessed by immunohistochemistry (IHC) 22C3 pharmDx assay (Dako North America, Inc.) at a central laboratory...
Trial ID:
Source:
Title:
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
Excerpt:
...Tumor tissue that demonstrates PD-L1 expression in ≥1% of tumor cells (TPS ≥1%) as assessed by IHC 22C3 pharmDx....
